Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2026 09:15 ET | Source: Biofrontera Inc.

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”),...
February 11, 2026 09:15 ET | Source: Biofrontera Inc.

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial...
January 08, 2026 08:45 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne...
December 18, 2025 08:45 ET | Source: Biofrontera Inc.

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted...
December 04, 2025 09:00 ET | Source: Biofrontera Inc.

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone...
November 13, 2025 08:15 ET | Source: Biofrontera Inc.

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company...
November 07, 2025 08:00 ET | Source: Biofrontera Inc.

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further...
October 31, 2025 11:11 ET | Source: Research and Markets

Europe Photodynamic Therapy Market Size, Trends, Leading Applications and Pricing Benchmarks (2025-2033) Featuring Gladerma, Sun Pharmaceutical, Biofrontera, Lumibird, Bausch Health Companies and More

Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Europe Photodynamic Therapy Market Size and Trends 2025-2033" has been added to ResearchAndMarkets.com's offering. The Europe Photodynamic Therapy...
October 23, 2025 08:45 ET | Source: Biofrontera Inc.

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate...
September 23, 2025 09:20 ET | Source: Biofrontera Inc.

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization...